Abstract: Antigen binding polypeptide specifically binding to a ?/? T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the ?/? TCR/CD3 complex.

Abstract: As is further apparent from FIGS. 1 to 4, the illustrated exemplary embodiment of the measuring apparatus 10 comprises a second housing 12 and a metal shielding plate 14 that encompasses the second housing 12. In so doing, the metal shielding plate 14 is formed in a closed manner and pushed over the second housing 12. The second housing 12 is formed in the illustrated exemplary embodiment as a synthetic material housing. The measuring element 16.2 is formed in the illustrated embodiment as a TMR component 16.2A that is based on the TMR effect (tunnel magneto-resistive effect) and cooperates with the permanent magnet 22 that is arranged on the end of the shaft 26A of the brushless EC motor in order to detect the prevailing rotational position of the shaft 26A. It is naturally also possible to use other measuring elements 16.2 that are suitable to detect the prevailing rotational position of the shaft.

Abstract: The present invention relates to antigen binding proteins that specifically bind to a tumor expressed melanoma-associated antigen (MAGE) B2 antigenic peptide in a complex with MHC. The antigen binding proteins are provided for use in the treatment of MAGEB2-expressing cancers. Further provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins.

Abstract: Technologies and techniques directed to a multifunctional operating device for a motor vehicle and a motor vehicle equipped with such a device. The operating device includes a multifunctional operating element for operating a plurality of predefined functions. These predefined functions include setting a volume for an acoustic output through a loudspeaker device and setting a driving experience. A driving operation mode and an ambience mode of the motor vehicle can be set using the operating element to customize the driving experience.

Abstract: Antigen binding polypeptide specifically binding to ?/? T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector, and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the ?/? TCR/CD3 complex.

Abstract: Provided is an extrusion system including an extruder and a die. The die includes a feed section with at least two ports for injecting a protein phase and/or fat phase, a feed channel, an extrusion plane with side walls and a die exit. Each of the ports is connected to an independent channel providing the protein phase and/or fate phase. The at least two ports lead into the feed channel. The feed channel leads to the extrusion plane such that the protein phase and/or fat phase is conveyed from the feed section to the extrusion plane. The extrusion plane has an isosceles triangular shape with the legs of the triangle forming the side walls and the base of the triangle forming the die exit. The feed channel leads into the extrusion plane at the apex of the triangle of the extrusion plane.

Abstract: A device for improved visualization of an indication in an instrument cluster of a transportation vehicle and a corresponding system, method and computer program. Due to the greatly limited display area of the mini-FID in the instrument cluster, the device displays traffic signs, supplementary signs and warning lights in one display region. The supplementary signs information is displayed in reduced size in response to a warning light appearing above the traffic signs in the display region.

Abstract: The invention relates to a device (2) for injecting spin-polarized electrons and for reflecting light, comprising at least one lattice structure (3) having a plurality of recesses (4), wherein the lattice structure (3) is designed to reflect the light, and wherein a respective injection contact (5, 6) for injecting spin-polarized electrons is arranged in at least some of the recesses (4).

Abstract: A cabin purification system for a vehicle includes an air inlet in communication with a fan, a light source emitting ultraviolet C light at a wavelength of from 100 nanometers to 280 nanometers, a photocatalytic oxidizer element, and an air outlet. The photocatalytic oxidizer element has a surface coating comprising anatase and rutile forms of TiO2. The surface coating is illuminated by the light source. The fan generates an air flow from outside the air inlet to the air outlet. The air flow passes the light source and the photocatalytic oxidizer where the surface coating converts H2O O3 and O2 in the air flow into H2O2 which is distributed into the vehicle cabin to purify it.

Abstract: An electromechanical brake pressure generator unit (10) of a brake-by-wire brake system can only be activated electronically and comprises a master brake cylinder (20), an electric motor (14) and a multi-stage intermediate transmission (16). A spindle-nut unit (18) comprises a nut (40) having a centring surface (42) by way of which the piston (48) of the master brake cylinder (20) is centred.

Abstract: A tool system for mounting an elastic sleeve includes a holdout tube supporting the elastic sleeve prior to and during mounting, the holdout tube having a longitudinal axis, an interface element movable along the longitudinal axis and transferring pressure onto the elastic sleeve to push the elastic sleeve off the holdout tube during mounting, and an actuation lever engaging the holdout tube at a fulcrum region of the actuation lever. The actuation lever has a pair of load arms partly encompassing the holdout tube. A load region is arranged at a peripheral end of each of the load arms. The actuation lever actuates the interface element by pressing the load regions of the actuation lever against the interface element.

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: A method for producing a gear shaft for an electromechanical brake booster having an electric motor and having a rotation/translation conversion gear, which converts a rotating drive movement of the electric motor into a linear movement for actuating a piston-cylinder unit for generating a hydraulic brake pressure, is provided, according to which a force transmission element is provided. A rotationally-symmetrical gearing is integrally formed on a drive-side end of the force transmission element. A positioning and fastening device is formed on the force transmission element at the output side, and a gearwheel is anchored on the force transmission element in a rotationally fixed manner by the positioning and fastening device. A gear shaft and a brake booster are also disclosed.

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: The present invention pertains to antigen recognizing constructs against COL6A3 antigens. The invention in particular provides novel engineered T cell receptor (TCR) based molecules which are selective and specific for the tumor expressing antigen COL6A3. The TCR of the invention, and COL6A3 antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of COL6A3 expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Abstract: The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a T cell receptor (TCR) being specific for a major histocompatibility complex (MHC)-associated peptide epitope, and a binding region derived from an antibody capable of recruiting human immune effector cells by specifically binding to a surface antigen of said cells, as well as methods of making the bispecific polypeptide molecule, and uses thereof.

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: The present invention concerns antigen binding proteins directed against PRAME protein-derived antigens. The invention in particular provides antigen binding proteins which are specific for the tumor expressed antigen PRAME, wherein the tumor antigen comprises or consists of SEQ ID NO: 50 and is in a complex with a major histocompatibility complex (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said PRAME peptide. The antigen binding proteins of the invention are for use in the diagnosis, treatment and prevention of PRAME expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising said nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.

Abstract: The present invention concerns antigen binding proteins specifically binding melanoma associated antigen A (MAGE-A) protein-derived antigens. The invention in particular provides antigen binding proteins which specifically bind to the MAGE-A antigenic peptide comprising or consisting of SEQ ID NO: 1 in a complex with a major histocombatibility (MHC) protein. The antigen binding proteins of the invention contain, in particular, the complementary determining regions (CDRs) of novel engineered T cell receptors (TCRs) that specifically bind to said MAGE-A peptide/MHC complex. The antigen binding proteins of the invention are of use for the diagnosis, treatment and prevention of MAGE-A expressing cancerous diseases. Further provided are nucleic acids encoding the antigen binding proteins of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins of the invention.